ARSA rs74315455: What Your Genotype Means

What each genotype means

Genetic Variant rs74315455 and Its Location

The single nucleotide polymorphism (SNP) rs74315455 resides on chromosome 22q13.33 inside the ARSA gene. At the nucleotide level on the ARSA coding sequence, this position corresponds to nucleotide position 302 (c.302G), where alternative nucleotide substitutions can occur, such as c.302G>T (p.Gly101Val) or c.302G>A (p.Gly101Asp). Because the orientation of the ARSA gene is transcribed from the genomic minus strand, raw genetic reports and direct-to-consumer platforms may display the alleles differently (for instance, showing C as the reference allele and A or T as alternates depending on the strand reported). In standard cDNA coding orientation, the reference allele is G, encoding a conserved glycine residue at position 101 of the arylsulfatase A enzyme. A base substitution changes this amino acid, generating an altered polypeptide chain that can affect the enzyme's structural stability, catalytic kinetics, or subsequent post-translational folding in the endoplasmic reticulum.

Biological Function of the ARSA Gene

The ARSA gene provides instructions for producing arylsulfatase A, an essential lysosomal enzyme responsible for hydrolyzing sulfatide lipids, particularly cerebroside 3-sulfate. Sulfatides are principal lipid constituents of the myelin sheath that insulates nerves throughout both the peripheral and central nervous systems. Under physiological conditions, arylsulfatase A breaks down sulfatides inside the lysosome with the assistance of an activator protein known as saposin B (encoded by the PSAP gene). When mutations disrupt arylsulfatase A synthesis, proper targeting, or catalytic activity, sulfatides cannot be degraded efficiently and accumulate progressively inside cellular lysosomes. This abnormal lipid storage leads to cellular toxicity, extensive loss of myelin (demyelination), and severe nervous system dysfunction. Normal biological function generally requires only a modest threshold of active enzyme, which is why individuals carrying one functional copy of the gene remain typically unaffected.

Clinical Evidence and Carrier Status

Pathogenic variants at rs74315455 are documented in ClinVar and clinical genetics literature as causative mutations for metachromatic leukodystrophy when inherited in trans with another pathogenic allele. Metachromatic leukodystrophy is inherited strictly in an autosomal recessive pattern. Clinical classifications assign pathogenic or likely pathogenic significance to the altered missense alleles at this locus, although global evidence strength for this specific variant is characterized as limited due to its extreme rarity in universal cohorts. Heterozygous individuals carrying one non-functional allele and one standard allele are classified as carriers. Carriers typically produce sufficient residual enzyme activity from the normal allele to prevent toxic sulfatide accumulation and do not develop neurological symptoms. However, if two carriers conceive, each pregnancy carries a 25% statistical probability of inheriting two altered copies and developing childhood-onset or late-onset leukodystrophy.

Population Frequency and Ancestry Trends

Variants at rs74315455 are exceptionally rare in the general worldwide population. According to population databases such as the Genome Aggregation Database (gnomAD), the overall global allele frequency is approximately 0.00002, indicating that the vast majority of human beings possess two copies of the reference allele. While the variant is observed at slightly elevated levels in cohorts of European descent, it remains exceedingly uncommon across all examined ancestries. Due to the very small absolute number of individuals carrying the variant in population-scale databases, frequency estimates are subject to statistical uncertainty. In the clinical context, metachromatic leukodystrophy has an estimated general incidence of 1 in 40,000 to 1 in 160,000 live births, driven by a heterogeneous spectrum of hundreds of distinct pathogenic mutations in the ARSA gene rather than a single predominant variant.

Interpreting Genetic Data and Clinical Next Steps

Identifying a variant at rs74315455 on consumer genotyping arrays requires careful clinical interpretation. Direct-to-consumer genotyping platforms frequently experience technical artifacts or false positives when calling ultra-rare single nucleotide variants. Therefore, unvalidated raw data cannot serve as a clinical diagnosis or definitive carrier screening result. If an individual receives a report suggesting carrier status, the finding should be verified through clinical-grade Sanger sequencing or targeted next-generation sequencing performed by an accredited molecular laboratory. Furthermore, individuals concerned about carrier status, reproductive planning, or family history of neurological conditions are encouraged to consult a certified genetic counselor or medical geneticist. Genetic professionals can evaluate comprehensive family health history, arrange validated carrier testing, assess pseudodeficiency alleles that can confound enzyme measurements, and discuss reproductive options.

Frequently asked questions

Sources & further reading